Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib

Abstract

Abstract. In the present study, the effect of immunophenotyping on the prognoses of patients with multiple myeloma (MM) treated with bortezomib plus dexamethasone was investigated. The study involved 46 patients with MM, and analyzed the prognostic significance of the expression of cluster of differentiation (CD)45, CD56 and mature plasma cell (MPC)-1, and other factors including the International Staging System (ISS) stage, age, gender, the immunoglobulin subtype and the treatment line number prior to bortezomib treatment. Although CD56 and MPC-1 expression did not appear to affect the time to next treatment (TNT) or overall survival rate (OS), the univariate analysis determined that CD45 positivity was an adverse prognostic factor for TNT and OS, and that being male was significantly associated with inferior TNT and OS. Multivariate analyses determined that CD45 expression was prognostically significant for TNT and OS. In conclusion, CD45 positivity is an adverse prognostic factor in MM patients treated with bortezomib. The data from the present study demonstrate the clinical importance of classifying MM cells immunophenotypically to determine the prognoses of patients.

Clinical effects of CD45 on the prognosis of extramedullary myeloma relapse

“…The expression of CD45− was associated with shorter survival in our MM patients with EMR in this study. CD45− myeloma cells is reported to be an unfavourable prognostic marker in the high‐dose therapy; however, opposite results are shown in the current studies carried out after the introduction of novel agents . This discrepancy is due to different treatment strategies and setting such as EMR.…”

“…CD45− myeloma cells is reported to be an unfavourable prognostic marker in the high-dose therapy 16 ; however, opposite results are shown in the current studies carried out after the introduction of novel agents. 17,18 This discrepancy is due to different treatment strategies and setting such as EMR. The present results showed that CD45 in bone marrow appears to be reliably expressed in EMR specimens.…”

“…CD45− myeloma cells are less sensitive to apoptosis, have a greater capacity to circulate, disseminate and clone and, thus, have a greater malignant potential . Moreau et al showed that CD45− myeloma cells were associated with a progressive clinical course and shorter survival ; however, other study showed that an increased proportion of CD45+ clonal MM cells in BM was associated with a poor prognosis . The relationship between CD45 expression and MM currently remains unclear.…”

“…16 Moreau et al showed that CD45− myeloma cells were associated with a progressive clinical course and shorter survival 16 ; however, other study showed that an increased proportion of CD45+ clonal MM cells in BM was associated with a poor prognosis. 17,18 The relationship between CD45 expression and MM currently remains unclear. Therefore, we herein investigated the relationship between CD45 expression and the prognosis of MM patients with EMR.…”

Relevance of diffusion-weighted imaging with background body signal suppression for staging, prognosis, morphology, treatment response, and apparent diffusion coefficient in plasma-cell neoplasms: A single-center, retrospective study

“…The immature type had a higher grade of malignancy that affected prognosis [21]. Thus, newly diagnosed MMs were classified into immature, intermediate, and mature types based on the presence or absence of MPC-1 and the expression of adhesion factors CD45 and CD49e [22][23][24]. The immature type demonstrated a larger nuclear size, narrower cytoplasm, and an increased nucleus-to-cytoplasm (N:C) ratio [25].…”